Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Talis Biomedical Temettü

Temettü kriter kontrolleri 0/6

Talis Biomedical şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.7%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$27.99
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Nov 04

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Jul 21

News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat

May 18

Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 14

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: TLIS şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: TLIS şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Talis Biomedical Piyasaya Karşı Temettü Getirisi

TLIS temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (TLIS)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Medical Equipment)	1.7%
Analist tahmini (TLIS) (3 yıla kadar)	0%

Önemli Temettü: TLIS şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, TLIS şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: TLIS şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: TLIS herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Talis Biomedical Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Talis Biomedical Corporation Files Form 15

Talis Biomedical Corporation(OTCPK:TLIS) dropped from NASDAQ Composite Index

Talis Biomedical Receives Non-Compliance Letter from Nasdaq Regarding Nasdaq Listing Rule 5101

Talis Biomedical Corporation announced delayed 10-Q filing

Talis Biomedical Corporation to Report Q2, 2023 Results on Aug 10, 2023

Talis Biomedical Corporation Announces New Data Supporting the Development of Its Planned CT/NG/TV and Vinal Infections Panels

Talis Biomedical Announces 1-For-15 Reverse Stock Split to Regain Compliance

Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors

Talis Biomedical Corporation Appoints Kimberly Popovits as Lead Independent Director

Talis Biomedical Corporation to Report Q1, 2023 Results on May 11, 2023

Talis Biomedical Transfers the Listing of Its Securities to the Nasdaq Capital Market

Price target decreased to US$0.40

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.98 loss per share (vs US$1.49 loss in 3Q 2021)

We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Talis Biomedical reports Q2 results

Talis Biomedical Corporation Announces Resignation of Raymond Cheong from Board of Directors

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$1.25

Less than half of directors are independent

Talis Biomedical Corporation Announces Board Changes

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Talis Biomedical Aims For Manufacturing Turnaround

Talis Biomedical Corporation to Report Q4, 2021 Results on Mar 15, 2022

The Klein Law Firm Announces Lead Plaintiff Deadline of March 8, 2022 in the Class Action Filed on Behalf of Talis Biomedical Corporation Shareholders

Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely

Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Filed Against Talis Biomedical Corporation

Levi & Korsinsky, LLP Notifies Shareholders of Talis Biomedical Corporation of A Class Action Lawsuit and A Lead Plaintiff Deadline

Glancy Prongay & Murray LLP Files Securities Lawsuit Against Talis Biomedical Corporation

Less than half of directors are independent

Third quarter 2021 earnings released: US$1.48 loss per share (vs US$13.90 loss in 3Q 2020)

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates fall to US$11.2m

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Talis Biomedical Corporation(NasdaqGM:TLIS) dropped from Russell Microcap Growth Index

Independent Director recently bought US$203k worth of stock

News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat

Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2021 earnings released: US$4.61 loss per share (vs US$56.61 profit in 1Q 2020)

Full year 2020 earnings released: US$42.98 loss per share (vs US$34.34 profit in FY 2019)

Talis Appoints Jeryl Hilleman to Board of Directors

Talis Biomedical Corporation Provides Update on Regulatory Pathway for Emergency Use Authorization (EUA) of Its Talis One™ Covid-19 Test

Talis Biomedical Corporation has completed an IPO in the amount of $220.8 million.

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin